clinical trial · NCT04045145
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia
CAH - Congenital Adrenal HyperplasiaCrinecerfont
brief summary
This is a Phase 2, open-label, multiple-dose, study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NBI-74788 (crinecerfont) in pediatric participants (14 to 17 years of age) with a documented medical diagnosis of classic 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH).
started
Dec 12, 2019
primary completion
Jul 2, 2021
completion
Jul 2, 2021
last updated
Jul 18, 2024
official title
A Phase 2, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Pediatric Subjects With Congenital Adrenal Hyperplasia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol